Your session is about to expire
← Back to Search
Device
Deep Brain Stimulation for Depression
N/A
Waitlist Available
Led By Jair C Soares, MD, PhD
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Recurrent (equal or >4 episodes) or chronic (episode duration equal or higher >2 years) course AND a minimum of 5 years since the onset of the first depressive episode
Major Depression Disorder (MDD) diagnosed by Structured Clinical Interview for DSM-IV (SCID I/DSM-IV), judged to be of disabling severity
Must not have
Surgical contraindications to undergoing DBS, refusal of an adequate trial of ECT, history of stimulation intolerance, current or unstably remitted substance abuse or dependence, pregnancy, history of severe personality disorder, imminent risk of suicide, participation in another drug, device, or biologics trial within the preceding 30 days, presence of a condition requiring routine MRIs, presence of a condition requiring diathermy, subject is on anticoagulant medication, not able to comply with the operational and administrative requirements of participation in the study, terminal illness associated with expected survival of <12 months
Any current clinically significant neurological disorder, including dementia or medical illness affecting brain function
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6, 12, and 24 months
Awards & highlights
No Placebo-Only Group
Summary
This trial will study the effects of DBS on the medial forebrain bundle to treat refractory depression in 20 patients.
Who is the study for?
This trial is for adults aged 22-70 with severe, treatment-resistant depression (TRD) who have tried multiple medications, psychotherapy, and possibly ECT without success. Participants must be in generally good health and not currently abusing substances. Pregnant women or those at risk of pregnancy without effective contraception are excluded.
What is being tested?
The study tests Deep Brain Stimulation (DBS) using the Percept™ PC system by Medtronic Neurological to target the medial forebrain bundle in patients with TRD. The goal is to see if DBS can reduce depressive symptoms in those who haven't responded to other treatments.
What are the potential side effects?
Potential side effects of DBS may include headache, seizure, confusion, hardware complications like lead displacement or infection, mood changes such as mania or apathy, and impaired coordination or speech.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My depression has recurred 4+ times or lasted 2+ years, starting over 5 years ago.
Select...
I have been diagnosed with severe depression.
Select...
I am between 22 and 70 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not have any brain-related health issues like dementia.
Select...
I've had surgery to target a specific area in my brain before.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6, 12, and 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6, 12, and 24 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Changes in patients MADRS scores
Secondary study objectives
Accuracy of Electrode placement
Assess maintenance of treatment response (or remission) associated with chronic DBS
Decrease in Neurocognitive scores on CSTC
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Deep Brain StimulationExperimental Treatment1 Intervention
Device implantation (Deep Brain Stimulation Model 3387 Model 3389)
Find a Location
Who is running the clinical trial?
MedtronicIndustry Sponsor
618 Previous Clinical Trials
763,997 Total Patients Enrolled
8 Trials studying Depression
70 Patients Enrolled for Depression
The University of Texas Health Science Center, HoustonLead Sponsor
946 Previous Clinical Trials
344,569 Total Patients Enrolled
18 Trials studying Depression
3,434 Patients Enrolled for Depression
Joao Quevedo, MD, PhDStudy DirectorThe University of Texas Health Science Center, Houston
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- The person has a score of at least 21 on the first 17 items on the Hamilton Depression Rating Scale.I do not have any brain-related health issues like dementia.I have had depression for over 5 years with severe impacts or hospital visits.I have tried multiple depression treatments without success, including medications, therapy, and ECT.My depression has recurred 4+ times or lasted 2+ years, starting over 5 years ago.I've had surgery to target a specific area in my brain before.I have been diagnosed with severe depression.I am between 22 and 70 years old.I have tried multiple antidepressants, ECT, and psychotherapy without success.I have been on the same mental health medication for at least 6 weeks.My main diagnosis is depression, not schizophrenia, bipolar, or severe anxiety.I have had depression for over 5 years with severe impacts or multiple hospital visits.Your ability to function in daily life is severely limited, with a score of 45 or less on a specific assessment.I have been on the same mental health medication for at least 6 weeks.I am between 22 and 70 years old.
Research Study Groups:
This trial has the following groups:- Group 1: Deep Brain Stimulation
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger